Developer docs
API playgroundTry for free, no card

Search company profiles

Stragen

Full company profile

uuid000am45

Namestring
Stragen
Legal namestring
Stragen
Websiteurl
stragen.ch
Company typeenum
Private
Founded yearint
1990
Descriptiontext

Stragen is a privately-held Swiss pharmaceutical company headquartered in Geneva, founded in 1990 by Jean-Luc Tetard, who continues to serve as CEO. The company develops, registers, and distributes generic medicines and consumer healthcare products across three product categories: Critical Care (hospital medicines for oncology, cardiology, neurology, infectious diseases and antifungals), Woman Health (oral contraceptives and endometriosis treatments), and Consumer Health (natural formulations for fertility, immunity, and metabolic disorders). Its core technology focus is on hard-to-make, high added-value and niche hospital medicines with specialized pharmaceutical forms and dosages tailored to hospital practices, supported by a dedicated scientific team operating under European manufacturing with an eco-responsible approach.

The company operates a sales-led, B2B-oriented go-to-market model, distributing products through 7 wholly-owned regional affiliate offices covering Denmark, Finland, Germany, Spain, France, the UK, and Saudi Arabia, reaching approximately 60 markets and 77% of the European population. Revenue is generated through one-time license-based sales of generic and specialty medicines to hospitals, healthcare professionals, and (in the consumer health category) end consumers via prescription and retail channels. Pricing is not publicly disclosed and varies by market and reimbursement system.

Stragen's subsidiary structure includes Stragen Global (headquarters operations), Stragen Nordic, Stragen Finland, Stragen GmbH (Germany), Stragen España, Stragen France, Stragen UK, and Stragen العربية (Arabia/Saudi Arabia). The company remains founder-controlled with no evidence of external institutional investment, M&A activity, or public listing. No financial figures, funding rounds, or AI/technology platform capabilities are disclosed in the available data.

Short descriptiontext

Stragen is a Swiss private pharmaceutical company, founded in 1990, that develops, registers, and distributes generic medicines and consumer healthcare products across 60 markets via 7 regional affiliates, serving hospitals, healthcare professionals, and patients in Europe and the Middle East.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPlan-les-ouates, Switzerland
HQ citystring
Plan-les-ouates
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, hospital medicines, women's health products, consumer healthcare, pharmaceutical distribution
Industry4 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAGAK
Women’s Health Supplements (Prenatal, Menopause, Hormonal)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Medicinal Chemicals & Botanical Products2833
Product category
Generic Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Generic Medicines Distribution
TypeOne Time License
Description

Development, registration, and distribution of generic medicines for hospital and retail use across therapeutic areas including oncology, cardiology, neurology, infectious diseases and antifungals.

stragen.com
2Consumer Healthcare Products
TypeOne Time License
Description

Natural formulations for consumer health including fertility, immunity and metabolic disorders. Products include oral contraceptives and treatments for endometriosis.

stragen.com
3Hospital/Prescription Medicines
TypeOne Time License
Description

Specialized hospital portfolio focusing on critical care therapeutic areas with unique dosages and pharmaceutical forms tailored to hospital practices.

stragen.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Critical Care
Description

Hospital portfolio focusing on therapeutic areas: oncology, cardiology, neurology, infectious diseases and antifungals.

stragen.com
+2 more records
Core offering1 text field

Stragen develops, registers, and distributes generic medicines and consumer healthcare products, with a particular focus on hard-to-make, high added-value, and niche hospital medicines. Its portfolio is organized into three segments—Critical Care (oncology, cardiology, neurology, infectious diseases, antifungals), Woman Health (oral contraceptives, endometriosis), and Consumer Health (natural formulations for fertility, immunity, metabolic disorders)—manufactured in Europe under an eco-responsible approach.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Stragen offers a unified portfolio of generic medicines and consumer healthcare products organized across three main categories: Critical Care (hospital medicines for oncology, cardiology, neurology, infectious diseases and antifungals), Woman Health (oral contraceptives and endometriosis treatments), and Consumer Health (natural formulations for fertility, immunity and metabolic disorders). All products are manufactured in Europe with an eco-responsible approach, targeting healthcare professionals and patients with innovative therapeutic solutions including hard-to-make, high-added-value and niche hospital medicines.

Product and service3 records
1Critical Care
CategoryGeneric Hospital Pharmaceuticals
Description

Hospital-focused generic medicine portfolio covering oncology, cardiology, neurology, infectious diseases, and antifungals, providing innovative therapeutic solutions with unique dosages and pharmaceutical forms tailored to hospital practices for healthcare professionals and hospital buyers.

2Woman Health
CategoryWomen's Health Pharmaceuticals
Description

Women's health product line including a range of oral contraceptives and products designed to address endometriosis-related issues, targeted at prescribers, pharmacies, and women's health clinics.

3Consumer Health
CategoryConsumer Healthcare
Description

Consumer healthcare products consisting of natural formulations crafted from carefully selected active ingredients based on scientific evidence, with expertise in fertility, immunity, and metabolic disorders for end consumers and consumer health distributors.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

Stragen provides daily support for healthcare professionals by providing them with innovative therapeutic solutions, sometimes unique with dosages and pharmaceutical forms tailored to hospital practices.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

South African-headquartered specialty pharmaceutical group with established European footprint and a portfolio spanning hospital specialty and women's health — comparable in multi-region affiliate model and therapeutic mix.

TypeDirect peer
Description

Hungarian specialty pharmaceutical company with significant women's health (contraceptives, gynecology) and specialty generics franchises across Europe — directly comparable to Stragen's combination of women's health and hard-to-make generics.

TypeDirect peer
Description

Slovenian generics manufacturer with broad European footprint and a portfolio spanning hospital and consumer health segments, built around cost-efficient European manufacturing — comparable business model to Stragen.

TypeDirect peer
Description

German-headquartered European specialty generics and consumer health company with a multi-country affiliate model and broad hospital/retail portfolio — closely mirrors Stragen's combination of specialty generics plus consumer health verticals across European markets.

TypeDirect peer
Description

UK-based specialty pharma dedicated to women's health (contraception, menopause, endometriosis-adjacent therapies) — closely overlaps with Stragen's Woman Health vertical of oral contraceptives and endometriosis products.

TypeBroad incumbent
Description

Global generics and specialty pharmaceutical major formed via Mylan-Upjohn combination, with broad European hospital and retail presence — a much larger incumbent operating in the same generic and specialty pharma space as Stragen.

7Sandoz
TypeBroad incumbent
Description

Novartis's generics and biosimilars division, with leading European hospital generics business and global distribution — operates in the same hospital generics category as Stragen but at significantly greater scale.

TypeBroad incumbent
Description

World's largest generics manufacturer with deep European presence across specialty, hospital, and women's health categories — broad incumbent overlapping with Stragen's therapeutic and geographic scope.

TypeDirect peer
Description

Global women's health pharmaceutical company with strong European presence in contraception and gynecology — comparable to Stragen's Woman Health segment in target therapeutic areas and customer base.

TypeDirect peer
Description

European generics company headquartered in Prague, with a multi-country affiliate model across Central and Western Europe focused on affordable medicines — closely comparable in geographic and channel strategy to Stragen.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stragen

Generic Pharmaceuticalsstragen.ch

Stragen is a Swiss private pharmaceutical company, founded in 1990, that develops, registers, and distributes generic medicines and consumer healthcare products across 60 markets via 7 regional affiliates, serving hospitals, healthcare professionals, and patients in Europe and the Middle East.

What Stragen does

Stragen is a privately-held Swiss pharmaceutical company headquartered in Geneva, founded in 1990 by Jean-Luc Tetard, who continues to serve as CEO. The company develops, registers, and distributes generic medicines and consumer healthcare products across three product categories: Critical Care (hospital medicines for oncology, cardiology, neurology, infectious diseases and antifungals), Woman Health (oral contraceptives and endometriosis treatments), and Consumer Health (natural formulations for fertility, immunity, and metabolic disorders). Its core technology focus is on hard-to-make, high added-value and niche hospital medicines with specialized pharmaceutical forms and dosages tailored to hospital practices, supported by a dedicated scientific team operating under European manufacturing with an eco-responsible approach.

The company operates a sales-led, B2B-oriented go-to-market model, distributing products through 7 wholly-owned regional affiliate offices covering Denmark, Finland, Germany, Spain, France, the UK, and Saudi Arabia, reaching approximately 60 markets and 77% of the European population. Revenue is generated through one-time license-based sales of generic and specialty medicines to hospitals, healthcare professionals, and (in the consumer health category) end consumers via prescription and retail channels. Pricing is not publicly disclosed and varies by market and reimbursement system.

Stragen's subsidiary structure includes Stragen Global (headquarters operations), Stragen Nordic, Stragen Finland, Stragen GmbH (Germany), Stragen España, Stragen France, Stragen UK, and Stragen العربية (Arabia/Saudi Arabia). The company remains founder-controlled with no evidence of external institutional investment, M&A activity, or public listing. No financial figures, funding rounds, or AI/technology platform capabilities are disclosed in the available data.

Stragen firmographics

Firmographics
Name
Stragen
Legal name
Stragen
Website
https://stragen.ch
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
101–250 employees
Short description
Stragen is a Swiss private pharmaceutical company, founded in 1990, that develops, registers, and distributes generic medicines and consumer healthcare products across 60 markets via 7 regional affiliates, serving hospitals, healthcare professionals, and patients in Europe and the Middle East.
Ownership category
akta.pro rank

Stragen industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAGAK
Women’s Health Supplements (Prenatal, Menopause, Hormonal)

Keywords

  • Generic pharmaceuticals
  • Hospital medicines
  • Women's health products
  • Consumer healthcare
  • Pharmaceutical distribution

Where Stragen is headquartered

Location

Headquarters

HQ city
Plan-les-ouates
HQ country
Switzerland
HQ region
Europe

Offices7 records

Markets served

Stragen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Generic Medicines Distribution: Development, registration, and distribution of generic medicines for hospital and retail use across therapeutic areas including oncology, cardiology, neurology, infectious diseases and antifungals.
  2. Consumer Healthcare Products: Natural formulations for consumer health including fertility, immunity and metabolic disorders. Products include oral contraceptives and treatments for endometriosis.
  3. Hospital/Prescription Medicines: Specialized hospital portfolio focusing on critical care therapeutic areas with unique dosages and pharmaceutical forms tailored to hospital practices.

Go-to-market motion1 record

Distribution channels1 record

Stragen product offering

Product offering

Core offering

Stragen develops, registers, and distributes generic medicines and consumer healthcare products, with a particular focus on hard-to-make, high added-value, and niche hospital medicines. Its portfolio is organized into three segments—Critical Care (oncology, cardiology, neurology, infectious diseases, antifungals), Woman Health (oral contraceptives, endometriosis), and Consumer Health (natural formulations for fertility, immunity, metabolic disorders)—manufactured in Europe under an eco-responsible approach.

Product overview

Stragen offers a unified portfolio of generic medicines and consumer healthcare products organized across three main categories: Critical Care (hospital medicines for oncology, cardiology, neurology, infectious diseases and antifungals), Woman Health (oral contraceptives and endometriosis treatments), and Consumer Health (natural formulations for fertility, immunity and metabolic disorders). All products are manufactured in Europe with an eco-responsible approach, targeting healthcare professionals and patients with innovative therapeutic solutions including hard-to-make, high-added-value and niche hospital medicines.

Differentiator

Problem solved

Functional benefit

Brands

  • Critical Care: Hospital portfolio focusing on therapeutic areas: oncology, cardiology, neurology, infectious diseases and antifungals.
  • Woman Health
  • Consumer Health

Products and services

  • Critical Care Hospital-focused generic medicine portfolio covering oncology, cardiology, neurology, infectious diseases, and antifungals, providing innovative therapeutic solutions with unique dosages and pharmaceutical forms tailored to hospital practices for healthcare professionals and hospital buyers.
  • Woman Health Women's health product line including a range of oral contraceptives and products designed to address endometriosis-related issues, targeted at prescribers, pharmacies, and women's health clinics.
  • Consumer Health Consumer healthcare products consisting of natural formulations crafted from carefully selected active ingredients based on scientific evidence, with expertise in fertility, immunity, and metabolic disorders for end consumers and consumer health distributors.

Companies that use Stragen

Customer profile

Segments3 records

Ideal customer profiles2 records

Stragen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Stragen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Healthcare ProfessionalscoreOthersStragen provides daily support for healthcare professionals by providing them with innovative therapeutic solutions, sometimes unique with dosages and pharmaceutical forms tailored to hospital practices.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Stragen competitors and assessment

Company assessment

Direct peers

  • Aspen Pharmacare: South African-headquartered specialty pharmaceutical group with established European footprint and a portfolio spanning hospital specialty and women's health — comparable in multi-region affiliate model and therapeutic mix.
  • Gedeon Richter: Hungarian specialty pharmaceutical company with significant women's health (contraceptives, gynecology) and specialty generics franchises across Europe — directly comparable to Stragen's combination of women's health and hard-to-make generics.
  • KRKA: Slovenian generics manufacturer with broad European footprint and a portfolio spanning hospital and consumer health segments, built around cost-efficient European manufacturing — comparable business model to Stragen.
  • Stada Arzneimittel: German-headquartered European specialty generics and consumer health company with a multi-country affiliate model and broad hospital/retail portfolio — closely mirrors Stragen's combination of specialty generics plus consumer health verticals across European markets.
  • Theramex: UK-based specialty pharma dedicated to women's health (contraception, menopause, endometriosis-adjacent therapies) — closely overlaps with Stragen's Woman Health vertical of oral contraceptives and endometriosis products.
  • Exeltis: Global women's health pharmaceutical company with strong European presence in contraception and gynecology — comparable to Stragen's Woman Health segment in target therapeutic areas and customer base.
  • Zentiva: European generics company headquartered in Prague, with a multi-country affiliate model across Central and Western Europe focused on affordable medicines — closely comparable in geographic and channel strategy to Stragen.

Broad incumbents

  • Viatris: Global generics and specialty pharmaceutical major formed via Mylan-Upjohn combination, with broad European hospital and retail presence — a much larger incumbent operating in the same generic and specialty pharma space as Stragen.
  • Sandoz: Novartis's generics and biosimilars division, with leading European hospital generics business and global distribution — operates in the same hospital generics category as Stragen but at significantly greater scale.
  • Teva Pharmaceutical Industries: World's largest generics manufacturer with deep European presence across specialty, hospital, and women's health categories — broad incumbent overlapping with Stragen's therapeutic and geographic scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Stragen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stragen leadership team

Management profile

Number of profiles

Profiles1 record

Stragen subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Stragen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stragen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stragen

What does Stragen do?

Stragen develops, registers, and distributes generic medicines and consumer healthcare products, with a particular focus on hard-to-make, high added-value, and niche hospital medicines. Its portfolio is organized into three segments—Critical Care (oncology, cardiology, neurology, infectious diseases, antifungals), Woman Health (oral contraceptives, endometriosis), and Consumer Health (natural formulations for fertility, immunity, metabolic disorders)—manufactured in Europe under an eco-responsible approach.

Is Stragen a public or private company?

Stragen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Stragen founded?

Stragen was founded in 1990. It employs 101 to 250 people.

Where is Stragen based?

Stragen is headquartered in Plan-les-ouates, Switzerland, in the Europe region.

How does Stragen make money?

Three revenue lines are on record. Generic Medicines Distribution is the primary driver. The others are consumer Healthcare Products and hospital/Prescription Medicines.

Who are Stragen's main competitors?

Direct peers on record are Aspen Pharmacare, Gedeon Richter, KRKA, Stada Arzneimittel, Theramex, Exeltis and Zentiva. Broad incumbents are Viatris, Sandoz and Teva Pharmaceutical Industries.

Does Stragen have an API?

No public API is recorded for Stragen.

What industry is Stragen in?

Stragen's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales